Consequently, this study shows that CD19 and CD81, which assign MM patients to three distinct groups of PCs differentiation, further associated with cumulative CNAs and CD117, allows the identification of new important prognostic subgroups, which may represent additional targets for specific studies and even for specific therapies. The gene discussed is CD19; the disease is Miyoshi myopathy.